enGene’s (ENGN) Buy Rating Reaffirmed at HC Wainwright

enGene (NASDAQ:ENGN)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $25.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 228.95% from the company’s current price.

Several other brokerages have also recently issued reports on ENGN. Jefferies Financial Group assumed coverage on enGene in a report on Friday, January 30th. They set a “buy” rating and a $28.00 price objective on the stock. Raymond James Financial reissued a “strong-buy” rating on shares of enGene in a research report on Monday. UBS Group boosted their price target on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price objective (up from $30.00) on shares of enGene in a research report on Wednesday, November 12th. Finally, Morgan Stanley upped their price target on shares of enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.29.

enGene Stock Down 12.4%

ENGN traded down $1.08 during trading on Monday, reaching $7.60. The stock had a trading volume of 476,890 shares, compared to its average volume of 336,012. The stock’s 50 day moving average is $9.58 and its two-hundred day moving average is $8.07. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. enGene has a one year low of $2.65 and a one year high of $12.25. The company has a market capitalization of $509.12 million, a price-to-earnings ratio of -3.32 and a beta of -0.29.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). As a group, analysts expect that enGene will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On enGene

Several large investors have recently made changes to their positions in ENGN. Perceptive Advisors LLC grew its position in enGene by 179.8% during the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after buying an additional 3,771,840 shares during the period. Siren L.L.C. purchased a new position in enGene during the fourth quarter worth approximately $30,126,000. Braidwell LP acquired a new stake in enGene in the third quarter valued at approximately $15,479,000. Janus Henderson Group PLC acquired a new stake in enGene in the fourth quarter valued at approximately $17,110,000. Finally, Cormorant Asset Management LP increased its position in shares of enGene by 72.1% in the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after buying an additional 1,676,405 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.